Joseph J. Ferra Jr. - 15 Feb 2025 Form 4 Insider Report for Elevation Oncology, Inc. (ELEV)

Signature
/s/ Robert Yang, Attorney-in-Fact
Issuer symbol
ELEV
Transactions as of
15 Feb 2025
Net transactions value
-$6,187
Form type
4
Filing time
19 Feb 2025, 16:10:07 UTC
Previous filing
18 Dec 2024
Next filing
18 Mar 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELEV Common Stock Options Exercise +25,000 +23% 134,482 15 Feb 2025 Direct F1
transaction ELEV Common Stock Tax liability $6,187 -9,211 -6.8% $0.6717 125,271 15 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELEV Stock Option (Right to Buy) Award $0 +800,000 $0.000000 800,000 15 Feb 2025 Common Stock 800,000 $0.6717 Direct F2
transaction ELEV Restricted Stock Unit Options Exercise $0 -25,000 -25% $0.000000 75,000 15 Feb 2025 Common Stock 25,000 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 The stock option vests as to 25% of the total shares on February 15, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F3 25% of the RSUs vested on February 15, 2025, and the remainder will vest as to 1/16 of the total RSUs quarterly until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
F4 The RSUs do not expire; they either vest or are canceled prior to the vesting date.